SCHEMBL710469

SCHEMBL710469

Cc1cc(-c2ccc(-c3ccccc3)cc2)nc2ccccc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.66
MAPT P10636 5/20 0.66
SMN1; SMN2 Q16637 4/20 0.66
MEN1 O00255 2/20 0.66
KMT2A Q03164 2/20 0.66
AHR P35869 1/20 0.62
LMNA P02545 4/20 0.61
KDM4E B2RXH2 4/20 0.61
RAB9A P51151 3/20 0.61
NPC1 O15118 2/20 0.61
HCRTR1 O43613 1/20 0.61
GAA P10253 1/20 0.61
THRB P10828 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
DHODH Q02127 3/20 0.58
CYP1A2 P05177 1/20 0.58
ACHE P22303 1/20 0.58
HPGD P15428 2/20 0.57
ACACA Q13085 2/20 0.55
BACE1 P56817 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL951744 0.96 MAPT (0.65) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL17600557 0.94 ALDH1A1 (0.63) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL30388558 0.94 ALDH1A1 (0.63) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL30946935 0.94 ALDH1A1 (0.63) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL6859623 0.94 ALDH1A1 (0.63) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL27986152 0.94 ALDH1A1 (0.63) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL26456461 0.91 ALDH1A1 (0.64) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL670646 0.89 CYP1A2 (0.62) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL10944758 0.88 ALDH1A1 (0.61) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL30028973 0.88 ALDH1A1 (0.61) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124625-B2 enhancing the expression of apoAI; prevention or therapy of dislipidemia SHIONOGI & CO., LTD. (JP) 2012-02-28 US disclosed
US-8053445-B2 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2011-11-08 US disclosed
EP-2168576-A2 New utilities of tricyclic compounds Shionogi & Co., Ltd. (JP) 2010-03-31 EP disclosed
US-20090036457-A1 Utilities of olefin derivatives YAMAMORI TERUO 2009-02-05 US disclosed
US-20080318958-A1 New utilities of tricyclic compounds ISHIZUKA NATSUKI 2008-12-25 US disclosed
US-20080318958-A1 New utilities of tricyclic compounds ISHIZUKA NATSUKI 2008-12-25 US disclosed
US-20040242615-A1 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242615-A1 Utilities of olefin derivatives APOL1, NR1H2, APOB ALDH1A1 1967/4885MAPT 3896/4885SMN1; SMN2 1814/4885
US-20080318958-A1 New utilities of tricyclic compounds APOB, PON1, APOL1 ALDH1A1 934/4885MAPT 4593/4885SMN1; SMN2 2752/4885
US-20090036457-A1 Utilities of olefin derivatives APOL1, APOB, NR1H2 ALDH1A1 1938/4885MAPT 3909/4885SMN1; SMN2 1978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.